Incyte (INCY) Non-Current Deffered Revenue (2010 - 2015)
Incyte (INCY) posted Non-Current Deffered Revenue of $2.9 million for Q3 2015, down 52.84% on a QoQ basis from $6.1 million in Q2 2015, and down 81.76% year-over-year from $15.7 million in Q3 2014.
Incyte (INCY) Non-Current Deffered Revenue (2010 - 2015) Analysis & Trends
Incyte's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $2.9 million for Q3 2015.
- Quarterly Non-Current Deffered Revenue fell 81.76% year-over-year to $2.9 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $2.9 million (down 81.76% YoY) and the FY2014 annual result came in at $12.5 million, down 50.68% from the prior year.
- Non-Current Deffered Revenue was $2.9 million for Q3 2015 at Incyte, down from $6.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $154.5 million in Q1 2011 and bottomed at $2.9 million in Q3 2015.
- A 5-year average of $51.4 million and a median of $31.8 million in 2013 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2013 — Non-Current Deffered Revenue tumbled 33.63% — and 2015, when it tumbled 81.76%.
- Incyte's Non-Current Deffered Revenue stood at $104.3 million in 2011, then plunged by 63.34% to $38.2 million in 2012, then plunged by 33.63% to $25.4 million in 2013, then slumped by 50.68% to $12.5 million in 2014, then tumbled by 77.07% to $2.9 million in 2015.
- Business Quant data shows INCY's Non-Current Deffered Revenue at $2.9 million in Q3 2015, $6.1 million in Q2 2015, and $9.3 million in Q1 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 2.87 Mn |
| Jun 30, 2015 | 6.08 Mn |
| Mar 31, 2015 | 9.30 Mn |
| Dec 31, 2014 | 12.51 Mn |
| Sep 30, 2014 | 15.73 Mn |
| Jun 30, 2014 | 18.94 Mn |
| Mar 31, 2014 | 22.15 Mn |
| Dec 31, 2013 | 25.37 Mn |
| Sep 30, 2013 | 28.58 Mn |
| Jun 30, 2013 | 31.80 Mn |
| Mar 31, 2013 | 35.01 Mn |
| Dec 31, 2012 | 38.23 Mn |
| Sep 30, 2012 | 54.06 Mn |
| Jun 30, 2012 | 70.80 Mn |
| Mar 31, 2012 | 87.54 Mn |
| Dec 31, 2011 | 104.27 Mn |
| Sep 30, 2011 | 121.01 Mn |
| Jun 30, 2011 | 137.75 Mn |
| Mar 31, 2011 | 154.48 Mn |
| Dec 31, 2010 | 171.22 Mn |